Adeia Inc. (NASDAQ: ADEA) reported first‑quarter 2026 revenue of $104.8 million, up 19% year‑over‑year from $87.7 million in Q1 2025 but down 42% sequentially from $182.6 million in Q4 2025. Operating cash flow reached $58.5 million and the company posted an adjusted EBITDA margin of 60%, a level that underscores disciplined cost control and a favorable mix of high‑margin licensing contracts. Non‑GAAP diluted earnings per share were $0.38, beating the consensus estimate of $0.36 by $0.02, or 5.6%—a beat driven largely by the 28% year‑over‑year growth in non‑Pay‑TV recurring revenue and the strong pricing power of new semiconductor and media deals.
The quarter’s revenue decline was largely attributable to a 42% sequential drop in Pay‑TV recurring revenue, a segment that has been pressured by subscriber churn and the timing of contract renewals. In contrast, non‑Pay‑TV recurring revenue grew 28% YoY, reflecting robust demand from semiconductor and consumer‑electronics customers. Management noted that “We believe our deal execution year‑to‑date highlights both the strength of our IP portfolio in core markets, like Pay‑TV, consumer electronics and social media, and our ability to expand our business with new customers in growth markets like semiconductors and e‑commerce.” The company also faced a headwind from a renewal dispute with DISH Network, which “We are disappointed we could not reach acceptable terms for a renewal with DISH Network after their agreement expired at the end of March, while adding, ‘we are confident we will reach successful outcomes with DISH and DIRECTV’.”
Adeia closed eight new license agreements during the quarter, including multi‑year deals with AMD and Microsoft. These contracts validate the company’s hybrid bonding technology for logic and memory applications and its RapidCool liquid‑cooling solutions, positioning Adeia in high‑growth AI and semiconductor markets. CEO Paul Davis emphasized the strategic significance, stating, “We had a strong start to 2026, delivering first quarter revenue of $105 million, generating $58 million in operating cash flow, and maintaining strong profitability with a 60% adjusted EBITDA margin. We closed eight license agreements during the quarter, three of which were with new customers, including multi‑year agreements with AMD and Microsoft.”
For the full year, Adeia reiterated revenue guidance of $395 million to $435 million and corrected operating‑expense guidance to $184 million to $192 million, a range that reflects the company’s focus on cost discipline amid a shift away from legacy Pay‑TV licensing. CFO Keith Jones confirmed the guidance, saying, “Our 2026 revenue guidance range is $395 million to $435 million and Operating expenses are expected to be in the range of $184 million to $192 million.” The company also announced a $10 million share‑repurchase and noted a current term‑loan balance of $398.6 million, underscoring its commitment to disciplined capital allocation. Investors reacted with caution, citing the guidance miss and the CEO succession announcement that “I have informed the Board of my intent to step down as CEO later this year… Our goal is to find the next leader for Adeia by the fourth quarter.”
Adeia’s debt profile has improved, with a credit rating upgrade from BB‑ to BB by S&P Global Ratings, reflecting stronger cash flows and a reduced leverage ratio. The company’s focus on hybrid bonding and RapidCool continues to drive high‑margin licensing opportunities, while the diversification into semiconductor and media markets mitigates the cyclical nature of Pay‑TV revenue. Overall, Adeia’s first‑quarter performance demonstrates resilient cash generation, disciplined cost management, and a strategic pivot toward high‑growth technology segments, positioning the company for continued execution in 2026 and beyond.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.